Related Experiment Video
Updated: May 28, 2025
Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice
Published on: February 18, 2017
3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor
Xingyun Yang1, Mara Artibani2,3, Yongcheng Jin1
1Department of Chemistry, University of Oxford, Oxford, OX1 3TA, UK.
Abstract:
The poor survival of ovarian cancer patients is linked to their high likelihood of relapse. In spite of full apparent macroscopic clearance, tumor recurrences arise from cells that are resistant to primary chemotherapy in the form of minimal residual disease (MRD). MRD exhibits distinct molecular drivers from bulk cancer and therefore necessitates alternative therapeutic strategies. However, there is a lack of 3D models that faithfully recapitulate MRD ex vivo for therapy development. This study constructs microfluidics-based 3D microtumors to generate a clinically-relevant model for ovarian cancer MRD. The microtumors recapitulate the non-genetic heterogeneity of ovarian cancer, capturing the "Oxford Classic" five molecular signatures. Gene expression in the 3D microtumors aligns closely with MRD from ovarian cancer patients and features the upregulation of fatty acid metabolism genes. Finally, the MRD 3D microtumors respond to the approved fatty acid oxidation inhibitor, perhexiline, demonstrating their utility in drug discovery. This system might be used as a drug-testing platform for the discovery of novel MRD-specific therapies in ovarian cancer.
Insights
Researchers developed a 3D microtumor model to study ovarian cancer minimal residual disease (MRD). This model successfully identified fatty acid metabolism as a target for new MRD-specific therapies.
Area of Science:
- Oncology
- Biomedical Engineering
- Drug Discovery
Background:
- Ovarian cancer patient survival is poor due to high relapse rates from chemotherapy-resistant minimal residual disease (MRD).
- MRD has distinct molecular drivers from bulk cancer, requiring novel therapeutic strategies.
- Existing 3D models do not accurately recapitulate ovarian cancer MRD ex vivo for therapy development.
Purpose of the Study:
- To construct a clinically relevant 3D microfluidics-based microtumor model for ovarian cancer MRD.
- To characterize the molecular profile and heterogeneity of this MRD model.
- To validate the model's utility in pre-clinical drug discovery for MRD-specific therapies.
Main Methods:
- Development of microfluidics-based 3D microtumors to model ovarian cancer MRD.
- Analysis of non-genetic heterogeneity and molecular signatures, including gene expression.
- Assessment of drug response using an approved fatty acid oxidation inhibitor, perhexiline.
Main Results:
- The 3D microtumors successfully recapitulated ovarian cancer non-genetic heterogeneity and molecular signatures.
- Gene expression in the microtumors closely matched patient MRD, showing upregulated fatty acid metabolism genes.
- The MRD 3D microtumors demonstrated therapeutic sensitivity to perhexiline, an inhibitor of fatty acid oxidation.
Conclusions:
- Microfluidics-based 3D microtumors provide a faithful ex vivo model for ovarian cancer MRD.
- The model highlights the role of fatty acid metabolism in MRD and identifies perhexiline as a potential therapeutic agent.
- This platform facilitates the discovery of novel, MRD-specific therapies for ovarian cancer.
